Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01159574|
Recruitment Status : Active, not recruiting
First Posted : July 9, 2010
Results First Posted : April 12, 2017
Last Update Posted : June 5, 2018
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: dexamethasone Drug: clarithromycin Drug: Pomalidomide||Phase 2|
This phase II study is a treatment program for patients with relapsed or refractory multiple myeloma who have had prior treatment with lenalidomide. Up to 54 patients will be enrolled. Patients who sign informed consent form and fulfill all eligibility criteria will be enrolled.
Dexamethasone (40mg ) on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.
Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle.
Serial clinic visits and laboratory measurements will be performed to monitor for treatment response. Those patients who demonstrate progression of disease at any point during ClaPd therapy will be taken off study.
At the end of every cycle (which may coincide with day 1 of the new cycle), response and toxicity will be evaluated. During cycle 1, patients will have labwork done weekly (CBC with differential and blood electrolytes). All patients will remain on study until disease progression or side effects become excessive. Patients who achieve a stable plateau may be taken off study if eligible to proceed to high dose chemotherapy and autologous stem cell transplantation.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||121 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Dexamethasone (DECADRON®), Clarithromycin (BIAXIN®), and Pomalidomide (CC-4047®) for Subjects With Relapsed or Refractory Multiple Myeloma|
|Actual Study Start Date :||August 2010|
|Actual Primary Completion Date :||October 2013|
|Estimated Study Completion Date :||June 2020|
Experimental: all patients
Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.
Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day.
40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
Other Name: Decadron
orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
Other Name: Biaxin
orally 4mg daily for days 1-21 of each 28 day cycle
Other Name: CC-4047
- Overall Response Rate [ Time Frame: from baseline to cycle with maximum response, which was achieved on average after 2 cycles ]Best response rate was recorded for all patients, using the IMWG criteria.
- Time to Maximum Response, Expressed as Number of Cycles of Treatment to Maximum Response [ Time Frame: From baseline to cycle of maximum response, which occurred on average after 2 cycles; 1 cycle = 28 days ]
- Time to Disease Progression (Progression Free Survival) [ Time Frame: From start of treatment, to date of disease progression ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01159574
|United States, New York|
|Weill Cornell Medical College|
|New York, New York, United States, 10065|
|Principal Investigator:||Ruben Niesvizky, MD||Weill Medical College of Cornell University|